Investors / filer profile

Seidenberg Beth C

active in 2 companies · 1 of 1 positions beat the S&P ~6mo later

Pro
Bought: Pro
Sold: 10
Filings: 2
Companies: 2026-08-10
Last filed

EDGAR · CIK 0001184592 ↗

Track record

How each disclosed position did against the S&P ~6 months later

The outcome curve and every position's resultPro →

+15.1%

median move per position

+9.7%

S&P 500 median, same spans

1 of 1

beat the S&P ~6mo later

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$1000.0K bought

All filings on record

Every Form 4 transaction we track for this filer


LTGOLatigo Biotherapeutics, Inc.	Convert — · 2,066,857 sh	2026-08-10	—
LTGOLatigo Biotherapeutics, Inc.	Convert — · 165,519 sh	2026-08-10	—
LTGOLatigo Biotherapeutics, Inc.	Convert — · 1,484,401 sh	2026-08-10	—
LTGOLatigo Biotherapeutics, Inc.	Convert — · 3,464,072 sh	2026-08-10	—
LTGOLatigo Biotherapeutics, Inc.	Convert — · 1,027,635 sh	2026-08-10	—
LTGOLatigo Biotherapeutics, Inc.	Convert — · 3,547,842 sh	2026-08-10	—
LTGOLatigo Biotherapeutics, Inc.	Convert — · 938,979 sh	2026-08-10	—
KYTXKyverna Therapeutics, Inc.	Grant — · 5,093 sh	2026-05-27	—
KYTXKyverna Therapeutics, Inc.	Buy $1000.0K · 133,333 sh	2025-12-18	—
KYTXKyverna Therapeutics, Inc.	Grant — · 16,634 sh	2025-05-29	—

LTGOConvert

2026-08-10 · Latigo Biotherapeutics, Inc.

2,066,857

—

LTGOConvert

2026-08-10 · Latigo Biotherapeutics, Inc.

165,519

—

LTGOConvert

2026-08-10 · Latigo Biotherapeutics, Inc.

1,484,401

—

LTGOConvert

2026-08-10 · Latigo Biotherapeutics, Inc.

3,464,072

—

LTGOConvert

2026-08-10 · Latigo Biotherapeutics, Inc.

1,027,635

—

LTGOConvert

2026-08-10 · Latigo Biotherapeutics, Inc.

3,547,842

—

LTGOConvert

2026-08-10 · Latigo Biotherapeutics, Inc.

938,979

—

KYTXGrant

2026-05-27 · Kyverna Therapeutics, Inc.

5,093

—

2025-12-18 · Kyverna Therapeutics, Inc.

$1000.0K

—

KYTXGrant

2025-05-29 · Kyverna Therapeutics, Inc.

16,634

—

10 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.